137.92
0.07%
+0.09
Neurocrine Biosciences, Inc. stock is currently priced at $137.92, with a 24-hour trading volume of 1.23M.
It has seen a +0.07% increased in the last 24 hours and a +2.42% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $137.7 pivot point. If it approaches the $141.9 resistance level, significant changes may occur.
Neurocrine Biosciences, Inc. Stock (NBIX) Financials Data
Neurocrine Biosciences, Inc. (NBIX) Revenue 2023
NBIX reported a revenue (TTM) of $1.89 billion for the quarter ending December 31, 2023, a +26.76% rise year-over-year.
Neurocrine Biosciences, Inc. (NBIX) Net Income 2023
NBIX net income (TTM) was $249.70 million for the quarter ending December 31, 2023, a +61.62% increase year-over-year.
Neurocrine Biosciences, Inc. (NBIX) Cash Flow 2023
NBIX recorded a free cash flow (TTM) of $361.60 million for the quarter ending December 31, 2023, a +11.99% increase year-over-year.
Neurocrine Biosciences, Inc. (NBIX) Earnings per Share 2023
NBIX earnings per share (TTM) was $2.42 for the quarter ending December 31, 2023, a +58.17% growth year-over-year.
Neurocrine Biosciences, Inc. Stock (NBIX) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Delaet Ingrid | Chief Regulatory Officer |
Mar 21 '24 |
Sale |
145.06 |
5,000 |
725,320 |
7,507 |
BENEVICH ERIC | Chief Commercial Officer |
Mar 14 '24 |
Option Exercise |
80.90 |
75,000 |
6,067,628 |
110,299 |
MORROW GEORGE J | Director |
Mar 14 '24 |
Option Exercise |
39.79 |
40,000 |
1,591,600 |
20,000 |
BENEVICH ERIC | Chief Commercial Officer |
Mar 14 '24 |
Sale |
139.38 |
75,000 |
10,453,417 |
40,778 |
MORROW GEORGE J | Director |
Mar 14 '24 |
Sale |
139.42 |
40,000 |
5,576,710 |
0 |
POPS RICHARD F | Director |
Mar 13 '24 |
Option Exercise |
42.76 |
23,200 |
992,032 |
52,712 |
Delaet Ingrid | Chief Regulatory Officer |
Mar 13 '24 |
Option Exercise |
106.02 |
3,000 |
318,060 |
10,507 |
POPS RICHARD F | Director |
Mar 13 '24 |
Sale |
140.33 |
23,200 |
3,255,621 |
29,512 |
Delaet Ingrid | Chief Regulatory Officer |
Mar 13 '24 |
Sale |
140.14 |
3,000 |
420,419 |
7,507 |
Delaet Ingrid | Chief Regulatory Officer |
Mar 11 '24 |
Option Exercise |
106.02 |
200 |
21,204 |
7,707 |
Neurocrine Biosciences, Inc. Stock (NBIX) Latest News
Analyst Bullish On Gene Therapy-Focused Voyager Therapeutics Sees Best In Class Potential For Its Neurogenetic Medicine Platform
Benzinga
In-Depth Examination Of 8 Analyst Recommendations For Neurocrine Biosciences
Benzinga
Decoding 8 Analyst Evaluations For Neurocrine Biosciences
Benzinga
Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?
Zacks Investment Research
Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
Zacks Investment Research
Why This Teva Pharmaceutical Analyst Is Turning Bullish On The Austedo Franchise
Benzinga
About Neurocrine Biosciences, Inc.
Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's lead products include INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; elagolix, a gonadotropin-releasing hormone (GnRH) antagonist that is in Phase III clinical trial for use in women's health; and opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trial that is used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease. It is also developing NBI-74788, which is in Phase II clinical trial that is used for the treatment of congenital adrenal hyperplasia. In addition, the company's research programs comprise VMAT2 Inhibitors for movement disorders, bipolar disorders, and schizophrenia; and G Protein-Coupled Receptors and Ion Channels for epilepsy, essential tremor, pain, dystonia, and other indications. It has collaborations and agreements with AbbVie Inc. to develop and commercialize elagolix and GnRH antagonists for women's and men's health; Mitsubishi Tanabe Pharma Corporation to develop and commercialize INGREZZA for movement disorders; and BIAL Portela & Ca, S.A. to develop and commercialize opicapone for the treatment of human diseases and conditions, including Parkinson's disease. The company also has a research collaboration agreement with Jnana Therapeutics Inc. to discover novel small molecule therapeutics for multiple targets for central nervous system disorders. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.
Cap:
|
Volume (24h):